Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Immucell (ICCC) Other Non Operating Income (2018 - 2024)

Historic Other Non Operating Income for Immucell (ICCC) over the last 6 years, with Q2 2024 value amounting to -$143679.0.

  • Immucell's Other Non Operating Income fell 9496.7% to -$143679.0 in Q2 2024 from the same period last year, while for Jun 2024 it was -$170865.0, marking a year-over-year increase of 1379.42%. This contributed to the annual value of -$21893.0 for FY2023, which is 8830.44% up from last year.
  • As of Q2 2024, Immucell's Other Non Operating Income stood at -$143679.0, which was down 9496.7% from -$136476.0 recorded in Q1 2024.
  • In the past 5 years, Immucell's Other Non Operating Income registered a high of $827690.0 during Q4 2020, and its lowest value of -$333776.0 during Q1 2020.
  • Its 5-year average for Other Non Operating Income is -$25980.6, with a median of -$70723.0 in 2020.
  • Examining YoY changes over the last 5 years, Immucell's Other Non Operating Income showed a top increase of 80966.85% in 2023 and a maximum decrease of 31403.9% in 2023.
  • Immucell's Other Non Operating Income (Quarter) stood at $827690.0 in 2020, then plummeted by 108.48% to -$70156.0 in 2021, then skyrocketed by 53.53% to -$32602.0 in 2022, then tumbled by 314.04% to -$134985.0 in 2023, then dropped by 6.44% to -$143679.0 in 2024.
  • Its Other Non Operating Income was -$143679.0 in Q2 2024, compared to -$136476.0 in Q1 2024 and -$134985.0 in Q4 2023.